Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of ...
- Patients achieving a high level of facial repigmentation (≥F-VASI90) at Week 52 maintained durable response one year following withdrawal of treatment - Continued treatment with Opzelura for up to two years resulted in sustained facial repigmentation and …